| 查看: 283 | 回复: 1 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Novo Nordisk receives approval for Victoza® in Japan
|
||
|
Novo Nordisk receives approval for Victoza® in Japan (20 January 2010) Read in PDF format Novo Nordisk receives approval for Victoza® in Japan Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. Victoza® is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes. "The Japanese approval of Victoza® represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk." says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza® will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza® to provide superior glucose control with a low risk of hypoglycaemia." Novo Nordisk expects to launch Victoza® in Japan in the first half of 2010 upon completion of price negotiations. |
回复此楼» 猜你喜欢
高效肺靶向RNA转染，加速肺部RNA药物开发
已经有2人回复
-
二糖的糖脂，合成后sephadex LH-20分离不出来，求助
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有82人回复
-
南方医科大学珠江医院肖计生课题组招收博士生 （2026年入学）
已经有2人回复
-
349药学专硕105500求调剂
已经有0人回复
-
求调剂
已经有1人回复
-
298求调剂一志愿中海洋
已经有3人回复
-
药学调剂申请自荐信，一志愿中南大学
已经有1人回复
-
药学349专硕求调剂
已经有1人回复
-
《左乙拉西坦注射液制备工艺研究、质量控制和稳定性研究》下载
已经有1人回复
2楼2010-01-20 20:07:57
